Dagytė Gertrūda, Mančinskaja Sofija, Krasauskienė Jurgita
Internal Medicine, Lithuanian University of Health Sciences, Kaunas, LTU.
Internal Medicine, Palliative Care and Family Health Center, Klaipėda, LTU.
Cureus. 2025 Mar 12;17(3):e80467. doi: 10.7759/cureus.80467. eCollection 2025 Mar.
Hashimoto's encephalopathy (HE), also known as steroid-responsive encephalopathy associated with autoimmune thyroiditis (SREAT), is a rare condition associated with thyroid autoimmunity. Characterized by cognitive decline, seizures, and neuropsychiatric symptoms, HE remains poorly understood and poses diagnostic challenges due to its variable criteria presentations and overlap with other conditions. Diagnosis typically involves clinical criteria, emphasizing encephalopathy in conjunction with positive thyroid antibodies, exclusion of alternative causes, and responsiveness to corticosteroid treatment. We present the case of a 76-year-old male patient admitted with acute gait disturbance and disorientation, later developing seizures and respiratory failure. Initial imaging demonstrated diffuse cortical atrophy, nonspecific white matter ischemic changes, and a right frontal meningioma. While infections and metabolic causes were ruled out, significantly elevated anti-thyroid peroxidase (ATPO) antibodies suggested HE. Corticosteroid therapy was administered with methylprednisolone pulse treatment (1 g/day for three days), leading to substantial neurological improvement and stabilization. Despite some residual ataxic symptoms, the patient's overall functional and cognitive status showed significant recovery. This case emphasizes the importance of considering HE in patients with unexplained encephalopathy and positive thyroid antibodies. Early intervention with corticosteroids can be vital in preventing lasting neurological damage. Continued research into HE is essential to refine diagnostic criteria, enhance differential diagnosis, and establish evidence-based treatment protocols that optimize patient outcomes.
桥本脑病(HE),也称为与自身免疫性甲状腺炎相关的类固醇反应性脑病(SREAT),是一种与甲状腺自身免疫相关的罕见病症。其特征为认知能力下降、癫痫发作和神经精神症状,由于其标准表现多样且与其他病症存在重叠,目前对HE的了解仍然有限,诊断也面临挑战。诊断通常涉及临床标准,重点是脑病伴有甲状腺抗体阳性、排除其他病因以及对皮质类固醇治疗有反应。我们报告一例76岁男性患者,因急性步态障碍和定向障碍入院,随后出现癫痫发作和呼吸衰竭。初始影像学检查显示弥漫性皮质萎缩、非特异性白质缺血性改变以及右侧额叶脑膜瘤。虽然排除了感染和代谢性病因,但抗甲状腺过氧化物酶(ATPO)抗体显著升高提示为HE。给予甲基泼尼松龙脉冲治疗(1克/天,共三天)的皮质类固醇疗法,使神经功能得到显著改善并稳定。尽管仍有一些残留的共济失调症状,但患者的整体功能和认知状态显示出明显恢复。该病例强调了在患有不明原因脑病且甲状腺抗体阳性的患者中考虑HE的重要性。早期使用皮质类固醇进行干预对于预防持久的神经损伤可能至关重要。对HE持续开展研究对于完善诊断标准、加强鉴别诊断以及制定优化患者预后的循证治疗方案至关重要。